Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome

Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, we investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patient...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 82; no. 4; pp. 1415 - 1421
Main Authors Lau, A S, Read, S E, Williams, B R
Format Journal Article
LanguageEnglish
Published Ann Arbor, MI American Society for Clinical Investigation 01.10.1988
Subjects
Online AccessGet full text
ISSN0021-9738
DOI10.1172/JCI113746

Cover

Abstract Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, we investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patients with AIDS, ARC, and heterosexual control subjects using radioiodinated IFN alpha 2 and IFN gamma. The binding characteristics of the 125I-IFN alpha and gamma to PBM were analyzed to determine receptor numbers and dissociation constants. PBM from controls expressed 498 +/- 247 IFN alpha receptor sites/cell (n = 17). However, eight patients with ARC and seven patients with AIDS had a mean number of IFN alpha receptor/cell of 286 +/- 235 (P less than 0.05) and 92 +/- 88 (P less than 0.001), respectively. This was consistent with elevated levels of serum acid-labile IFN alpha and cellular 2-5A synthetase activity in patients. Treatment of PBM from the AIDS patients with exogenous IFN alpha in vitro resulted in minimal 2-5A synthetase induction in comparison to controls. In contrast, the expression of IFN gamma receptors in ARC (n = 5) and AIDS (n = 4) patients remained normal. Thus the decrease in IFN alpha receptor expression and consequent hyporesponsiveness to IFN alpha raises the question of the usefulness of IFN alpha therapy in end-stage AIDS. The normal expression of IFN gamma receptors in AIDS patients suggests that IFN gamma may prove useful in attempts to provide immune reconstitution.
AbstractList Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, we investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patients with AIDS, ARC, and heterosexual control subjects using radioiodinated IFN alpha 2 and IFN gamma. The binding characteristics of the 125I-IFN alpha and gamma to PBM were analyzed to determine receptor numbers and dissociation constants. PBM from controls expressed 498 +/- 247 IFN alpha receptor sites/cell (n = 17). However, eight patients with ARC and seven patients with AIDS had a mean number of IFN alpha receptor/cell of 286 +/- 235 (P less than 0.05) and 92 +/- 88 (P less than 0.001), respectively. This was consistent with elevated levels of serum acid-labile IFN alpha and cellular 2-5A synthetase activity in patients. Treatment of PBM from the AIDS patients with exogenous IFN alpha in vitro resulted in minimal 2-5A synthetase induction in comparison to controls. In contrast, the expression of IFN gamma receptors in ARC (n = 5) and AIDS (n = 4) patients remained normal. Thus the decrease in IFN alpha receptor expression and consequent hyporesponsiveness to IFN alpha raises the question of the usefulness of IFN alpha therapy in end-stage AIDS. The normal expression of IFN gamma receptors in AIDS patients suggests that IFN gamma may prove useful in attempts to provide immune reconstitution.
Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, we investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patients with AIDS, ARC, and heterosexual control subjects using radioiodinated IFN alpha 2 and IFN gamma. The binding characteristics of the 125I-IFN alpha and gamma to PBM were analyzed to determine receptor numbers and dissociation constants. PBM from controls expressed 498 +/- 247 IFN alpha receptor sites/cell (n = 17). However, eight patients with ARC and seven patients with AIDS had a mean number of IFN alpha receptor/cell of 286 +/- 235 (P less than 0.05) and 92 +/- 88 (P less than 0.001), respectively. This was consistent with elevated levels of serum acid-labile IFN alpha and cellular 2-5A synthetase activity in patients. Treatment of PBM from the AIDS patients with exogenous IFN alpha in vitro resulted in minimal 2-5A synthetase induction in comparison to controls. In contrast, the expression of IFN gamma receptors in ARC (n = 5) and AIDS (n = 4) patients remained normal. Thus the decrease in IFN alpha receptor expression and consequent hyporesponsiveness to IFN alpha raises the question of the usefulness of IFN alpha therapy in end-stage AIDS. The normal expression of IFN gamma receptors in AIDS patients suggests that IFN gamma may prove useful in attempts to provide immune reconstitution.Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, we investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patients with AIDS, ARC, and heterosexual control subjects using radioiodinated IFN alpha 2 and IFN gamma. The binding characteristics of the 125I-IFN alpha and gamma to PBM were analyzed to determine receptor numbers and dissociation constants. PBM from controls expressed 498 +/- 247 IFN alpha receptor sites/cell (n = 17). However, eight patients with ARC and seven patients with AIDS had a mean number of IFN alpha receptor/cell of 286 +/- 235 (P less than 0.05) and 92 +/- 88 (P less than 0.001), respectively. This was consistent with elevated levels of serum acid-labile IFN alpha and cellular 2-5A synthetase activity in patients. Treatment of PBM from the AIDS patients with exogenous IFN alpha in vitro resulted in minimal 2-5A synthetase induction in comparison to controls. In contrast, the expression of IFN gamma receptors in ARC (n = 5) and AIDS (n = 4) patients remained normal. Thus the decrease in IFN alpha receptor expression and consequent hyporesponsiveness to IFN alpha raises the question of the usefulness of IFN alpha therapy in end-stage AIDS. The normal expression of IFN gamma receptors in AIDS patients suggests that IFN gamma may prove useful in attempts to provide immune reconstitution.
Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, the authors investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patients with AIDS, ARC, and heterosexual control subjects using radioiodinated IFN alpha sub(2) and IFN gamma . PBM from controls expressed 498 plus or minus 247 IFN alpha receptor sites/cell. However, eight patients with ARC and seven patients with AIDS had a mean number of IFN alpha receptor/cell of 286 plus or minus 235 and 92 plus or minus 88, respectively. In contrast, the expression of IFN gamma receptors in ARC and AIDS patients remained normal.
Author Lau, A S
Read, S E
Williams, B R
AuthorAffiliation Division of Infectious Diseases, Hospital for Sick Children, Toronto, Ontario, Canada
AuthorAffiliation_xml – name: Division of Infectious Diseases, Hospital for Sick Children, Toronto, Ontario, Canada
Author_xml – sequence: 1
  givenname: A S
  surname: Lau
  fullname: Lau, A S
– sequence: 2
  givenname: S E
  surname: Read
  fullname: Read, S E
– sequence: 3
  givenname: B R
  surname: Williams
  fullname: Williams, B R
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7272295$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/2971677$$D View this record in MEDLINE/PubMed
BookMark eNqFkj1vFDEQhl0EhXxQ8AOQXCAkiiO212ufCwp0fCWKlAZqa9Y7e2e0a29s78H9e_bIceKjSDOj0fu8o7FnzslJiAEJec7ZG861uLpZXXNeaalOyBljgi-MrpZPyXnO3xjjUtbylJwKo7nS-oxs38fvIeF66qH4GGjsqA8FU4dprqAfN0CbqdAQC13DMABN6HAsMVH8MSbMee_ygW79Nu5z2SAFdz_5hC31wzCF2GLnncfgdjTvQpvigJfkSQd9xmeHfEG-fvzwZfV5cXv36Xr17nbhKinVQnJ0rJZGO-harNiStbxxjus5sEZB17SiVoC61Yo1rmnQaOC1QWGgW1amuiBvH_qOUzNg6zCUBL0dkx8g7WwEb_9Wgt_YddxaKYUye_-rgz_F-wlzsYPPDvseAsYpW72c_9MI8SjIa6aErNQMvvhzouMoh43M-suDDtlB3yUIzucjpoUWwtQzdvWAuRRzTthZ58uvFc7P8L3lzO6vwR6vYXa8_sfxu-f_7E9NCLqZ
CODEN JCINAO
CitedBy_id crossref_primary_10_1097_00006454_199607000_00002
crossref_primary_10_1182_blood_2008_11_190231
crossref_primary_10_1016_j_cytogfr_2017_04_004
crossref_primary_10_1089_aid_2007_0261
crossref_primary_10_1089_aid_1992_8_199
crossref_primary_10_1016_0168_8278_92_90173_M
crossref_primary_10_1016_0090_1229_90_90082_2
crossref_primary_10_1089_jir_1998_18_209
crossref_primary_10_1016_j_cytogfr_2018_03_003
crossref_primary_10_1089_aid_1991_7_545
crossref_primary_10_1016_S0889_8553_05_70296_X
crossref_primary_10_1007_BF01878118
crossref_primary_10_1016_S0025_7125_16_30378_9
crossref_primary_10_1016_S0923_2494_05_80052_5
crossref_primary_10_1089_aid_1990_6_1149
crossref_primary_10_1097_QAI_0000000000001280
crossref_primary_10_1016_j_vascn_2004_02_003
crossref_primary_10_1189_jlb_68_3_391
crossref_primary_10_1002_hep_1840130221
crossref_primary_10_1186_1742_4690_1_29
crossref_primary_10_1097_01_aids_0000233571_51899_ab
crossref_primary_10_1073_pnas_94_21_11595
crossref_primary_10_1074_jbc_M304676200
crossref_primary_10_1089_jir_1996_16_127
crossref_primary_10_1128_JVI_76_16_8433_8445_2002
crossref_primary_10_1007_BF01299868
crossref_primary_10_1016_0268_960X_94_90112_0
crossref_primary_10_1128_JVI_01953_20
crossref_primary_10_1089_aid_1993_9_1115
ContentType Journal Article
Copyright 1989 INIST-CNRS
Copyright_xml – notice: 1989 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7U9
8FD
FR3
H94
M7Z
P64
7X8
5PM
DOI 10.1172/JCI113746
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biochemistry Abstracts 1
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Technology Research Database
Biochemistry Abstracts 1
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Virology and AIDS Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage 1421
ExternalDocumentID PMC442699
2971677
7272295
10_1172_JCI113746
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
.GJ
29K
2WC
3O-
53G
5GY
5RE
8F7
AAWTL
AAYXX
ABOCM
ACGFO
ACIHN
ACNCT
ACPRK
ADBBV
AEAQA
AENEX
AFFNX
AHMBA
AI.
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
CS3
D-I
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FRP
GROUPED_DOAJ
GX1
HYE
H~9
IAO
IEA
IHR
INH
IOF
IPO
J5H
KQ8
L7B
M1P
MVM
OK1
OVT
P2P
P6G
RPM
TEORI
TR2
TVE
VH1
VVN
W2D
WH7
WOQ
WOW
X7M
YOC
ZGI
ZXP
ZY1
.XZ
08G
08P
354
36B
5RS
7RV
7X7
88E
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
AAKAS
ABPMR
ABUWG
ADZCM
AFCHL
AFKRA
ASPBG
AVWKF
AZFZN
BBNVY
BCR
BCU
BEC
BENPR
BHPHI
BKEYQ
BLC
BPHCQ
BVXVI
CCPQU
EBD
EMOBN
EX3
FEDTE
FYUFA
HCIFZ
HMCUK
HVGLF
IHW
IOV
IQODW
ISR
ITC
LK8
M5~
M7P
N4W
NAPCQ
OBH
OCB
ODZKP
OFXIZ
OGEVE
OHH
OHT
OVD
OVIDX
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
Q2X
S0X
SJFOW
SV3
UHU
UKHRP
XSB
YFH
YHG
YKV
~H1
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7U9
8FD
FR3
H94
M7Z
P64
7X8
5PM
ID FETCH-LOGICAL-c3446-41ec05497cafde3080d1bcc17bcc0b6afbd256ae7d760bcbbe97a159e29af8393
ISSN 0021-9738
IngestDate Thu Aug 21 13:57:58 EDT 2025
Fri Sep 05 13:44:39 EDT 2025
Thu Sep 04 18:56:53 EDT 2025
Tue Aug 05 11:38:39 EDT 2025
Mon Jul 21 09:14:06 EDT 2025
Thu Apr 24 23:02:32 EDT 2025
Tue Jul 01 01:43:20 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Human
Immunopathology
Enzyme
Alpha interferon
AIDS
Hemopathy
Blood
Infection
Mononuclear cell
Viral disease
(2',5')A-Synthetase
AIDS related complex
Quantitative analysis
Gamma interferon
Biological receptor
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3446-41ec05497cafde3080d1bcc17bcc0b6afbd256ae7d760bcbbe97a159e29af8393
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink http://www.jci.org/articles/view/113746/files/pdf
PMID 2971677
PQID 15062436
PQPubID 23462
PageCount 7
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_442699
proquest_miscellaneous_78454922
proquest_miscellaneous_15062436
pubmed_primary_2971677
pascalfrancis_primary_7272295
crossref_citationtrail_10_1172_JCI113746
crossref_primary_10_1172_JCI113746
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 19881001
PublicationDateYYYYMMDD 1988-10-01
PublicationDate_xml – month: 10
  year: 1988
  text: 19881001
  day: 1
PublicationDecade 1980
PublicationPlace Ann Arbor, MI
PublicationPlace_xml – name: Ann Arbor, MI
– name: United States
PublicationTitle The Journal of clinical investigation
PublicationTitleAlternate J Clin Invest
PublicationYear 1988
Publisher American Society for Clinical Investigation
Publisher_xml – name: American Society for Clinical Investigation
References 6422299 - N Engl J Med. 1984 Apr 5;310(14):883-9
6712031 - Ann Intern Med. 1984 May;100(5):671-6
6229182 - Am J Med. 1984 Jan;76(1):95-100
6689734 - N Engl J Med. 1984 Jan 5;310(1):15-8
2996405 - Ann Intern Med. 1985 Nov;103(5):714-8
6086635 - J Biol Chem. 1984 Aug 10;259(15):9456-60
14450081 - Nature. 1962 May 5;194:495-6
6314645 - Virology. 1983 Oct 15;130(1):195-203
6189183 - Science. 1983 May 20;220(4599):868-71
6254391 - Anal Biochem. 1980 Sep 1;107(1):220-39
3009549 - J Clin Invest. 1986 May;77(5):1632-8
2411826 - J Infect Dis. 1985 Sep;152(3):466-72
6283974 - Ann Intern Med. 1982 Jun;96(6 Pt 1):700-4
2993441 - J Infect Dis. 1985 Sep;152(3):457-65
2940085 - Eur J Biochem. 1986 May 15;157(1):187-93
6327298 - Eur J Biochem. 1984 May 2;140(3):461-7
6318629 - Ann Intern Med. 1984 Jan;100(1):92-106
2857946 - Lancet. 1985 Mar 16;1(8429):602-4
6835320 - N Engl J Med. 1983 May 5;308(18):1071-6
2582258 - N Engl J Med. 1985 Jul 11;313(2):79-84
6979709 - N Engl J Med. 1982 Jul 22;307(4):232-6
3872068 - Am J Med. 1985 Mar;78(3):417-22
3008172 - Prog Clin Biol Res. 1985;202:405-13
6410234 - N Engl J Med. 1983 Sep 8;309(10):583-6
6143040 - Lancet. 1984 Mar 31;1(8379):698-702
2415141 - Annu Rev Immunol. 1985;3:477-500
3838854 - Am J Med. 1985 May;78(5):737-41
6224088 - N Engl J Med. 1983 Aug 25;309(8):453-8
6606643 - J Clin Immunol. 1983 Oct;3(4):332-40
6301456 - Biochem Biophys Res Commun. 1983 Jan 27;110(2):537-44
6125777 - Lancet. 1982 Sep 18;2(8299):631-3
6283973 - Ann Intern Med. 1982 Jun;96(6 Pt 1):693-700
6606691 - J Infect Dis. 1983 Dec;148(6):962-6
6439741 - J Clin Invest. 1984 Dec;74(6):2089-96
6200936 - Science. 1984 May 4;224(4648):500-3
6172066 - Ann Intern Med. 1982 Jan;96(1):80-93
7119475 - J Infect Dis. 1982 Oct;146(4):451-9
References_xml – reference: 6125777 - Lancet. 1982 Sep 18;2(8299):631-3
– reference: 6979709 - N Engl J Med. 1982 Jul 22;307(4):232-6
– reference: 6189183 - Science. 1983 May 20;220(4599):868-71
– reference: 6283973 - Ann Intern Med. 1982 Jun;96(6 Pt 1):693-700
– reference: 3872068 - Am J Med. 1985 Mar;78(3):417-22
– reference: 6439741 - J Clin Invest. 1984 Dec;74(6):2089-96
– reference: 2940085 - Eur J Biochem. 1986 May 15;157(1):187-93
– reference: 3008172 - Prog Clin Biol Res. 1985;202:405-13
– reference: 2411826 - J Infect Dis. 1985 Sep;152(3):466-72
– reference: 6314645 - Virology. 1983 Oct 15;130(1):195-203
– reference: 3009549 - J Clin Invest. 1986 May;77(5):1632-8
– reference: 6410234 - N Engl J Med. 1983 Sep 8;309(10):583-6
– reference: 3838854 - Am J Med. 1985 May;78(5):737-41
– reference: 2993441 - J Infect Dis. 1985 Sep;152(3):457-65
– reference: 6689734 - N Engl J Med. 1984 Jan 5;310(1):15-8
– reference: 6301456 - Biochem Biophys Res Commun. 1983 Jan 27;110(2):537-44
– reference: 2415141 - Annu Rev Immunol. 1985;3:477-500
– reference: 6283974 - Ann Intern Med. 1982 Jun;96(6 Pt 1):700-4
– reference: 2996405 - Ann Intern Med. 1985 Nov;103(5):714-8
– reference: 6318629 - Ann Intern Med. 1984 Jan;100(1):92-106
– reference: 14450081 - Nature. 1962 May 5;194:495-6
– reference: 6835320 - N Engl J Med. 1983 May 5;308(18):1071-6
– reference: 6422299 - N Engl J Med. 1984 Apr 5;310(14):883-9
– reference: 6224088 - N Engl J Med. 1983 Aug 25;309(8):453-8
– reference: 6712031 - Ann Intern Med. 1984 May;100(5):671-6
– reference: 6327298 - Eur J Biochem. 1984 May 2;140(3):461-7
– reference: 6229182 - Am J Med. 1984 Jan;76(1):95-100
– reference: 6143040 - Lancet. 1984 Mar 31;1(8379):698-702
– reference: 6200936 - Science. 1984 May 4;224(4648):500-3
– reference: 6606691 - J Infect Dis. 1983 Dec;148(6):962-6
– reference: 6606643 - J Clin Immunol. 1983 Oct;3(4):332-40
– reference: 6172066 - Ann Intern Med. 1982 Jan;96(1):80-93
– reference: 7119475 - J Infect Dis. 1982 Oct;146(4):451-9
– reference: 2857946 - Lancet. 1985 Mar 16;1(8429):602-4
– reference: 6086635 - J Biol Chem. 1984 Aug 10;259(15):9456-60
– reference: 2582258 - N Engl J Med. 1985 Jul 11;313(2):79-84
– reference: 6254391 - Anal Biochem. 1980 Sep 1;107(1):220-39
SSID ssj0014454
Score 1.4818805
Snippet Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1415
SubjectTerms 2',5'-Oligoadenylate Synthetase - metabolism
acquired immune deficiency syndrome
Acquired Immunodeficiency Syndrome - blood
Acquired Immunodeficiency Syndrome - enzymology
Adult
AIDS-Related Complex - enzymology
AIDS-Related Complex - metabolism
alpha -interferon
Biological and medical sciences
Blood Physiological Phenomena
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Interferon Type I - metabolism
Interferon-gamma - metabolism
leukocytes (mononuclear)
Leukocytes, Mononuclear - classification
Leukocytes, Mononuclear - enzymology
Leukocytes, Mononuclear - metabolism
Male
Medical sciences
Receptors, Immunologic - analysis
Receptors, Immunologic - metabolism
Receptors, Interferon
Title Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome
URI https://www.ncbi.nlm.nih.gov/pubmed/2971677
https://www.proquest.com/docview/15062436
https://www.proquest.com/docview/78454922
https://pubmed.ncbi.nlm.nih.gov/PMC442699
Volume 82
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVgCDQJIb4mCgwsxANSFdbEbpw8wgBtg_EAm7S3yl-BSjSpurSa9uu5N3acZnQS8JJWseukOSfWtX3PMSGvDROGGSMjNc5inK2yUSYzHhUaxh6s0CPNUOB8_DU9OOVHZ-OzLpW3UZfU6q2-3Kgr-R9U4RzgiirZf0A2NAon4DvgC0dAGI5_hfEHGEIv3GbyPu5D94dFYReYY4wq2qFa1sOyqoc_5Gwmh9C92XmNJt8XPgG2SXRcTVdVm_AoNeYGQxg6ReVIZSxaTDT6zE3mBp2yrIlpg85y2tl3dOv8X-TSdUUhAP3mGfa9E0SsTwC99-mMxsn0sizkt3UqgTjKhXNuaXvaLFljFF_rNmPuNJ1_9ucC_WGP9g_jmAk3V7mG63zWAJugDZbfDKbvne1LbpJbiRBuFf_wc1hk4nzsTbrdrXrjKbjmXrjiNrntG-kFLnfn8hyeZuE2P9k0OrmaZLsWtZzcJ_c8NPSd484DcsOWD8mdY59Q8Yis-hSiVUE7CtGGQhQoRIFCtKEQbSlEOwrBTyhSCD-BQrSlEL1KIdpS6DE5_fTxZP8g8ltxRJrBSxvx2GoI7nOhZWEsg2GGiZXWsYDDSKWyUAZiZ2mFEelIaaVsLiREyjbJZQExONshW2VV2ieEJiqT-SjVLOMZH-epTEWBq-VQVTET6wF50z7nifY-9bhdyq9JM14VySSAMyCvQtW5M2fZVGm3B1aoiSkIST4ekJcteBPoWnG9TJa2Wp5P0Hwz4Sy9voaAf8DzJBmQHQd2aNyTZkDSHgtCObq690vK6c_G3Z2juDx_el2Lz8h29749J1v1Yml3IS6u1YuG3b8BATO_OA
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Downregulation+of+interferon+alpha+but+not+gamma+receptor+expression+in+vivo+in+the+acquired+immunodeficiency+syndrome&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Lau%2C+A+S&rft.au=Read%2C+S+E&rft.au=Williams%2C+B+R&rft.date=1988-10-01&rft.issn=0021-9738&rft.volume=82&rft.issue=4&rft.spage=1415&rft_id=info:doi/10.1172%2FJCI113746&rft_id=info%3Apmid%2F2971677&rft.externalDocID=2971677
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon